Harrow Inc (HROW)

$35.21 -0.18 (-0.51%)
Market Cap 1.28B
Revenue (ttm) 272.30M
Net Income (ttm) -5.14M
EPS (ttm) N/A
PE Ratio 170.85
Forward PE 118.65
Profit Margin -1.89%
Debt to Equity Ratio 10.30
Volume 954,200
Avg Vol 736,342
Day's Range N/A - N/A
Shares Out 37.28M
Stochastic %K 90%
Beta 0.34
Analysts Strong Sell
Price Target $65.57

Company Profile

Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products in the United States. It operates through Branded and ImprimisRx segments. The company offers ImprimisRx, an ophthalmology-focused compounded medications. It also provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic solutions, including IOPIDINE, VEVYE, and ZERVIATE, as well as BYQLOVI; MAXITROL eye drops; ILEVRO and NEVANAC, a...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 615 733 4730
Address:
1A Burton Hills Boulevard, Suite 200, Nashville, United States
Finnish_boy
Finnish_boy May. 29 at 8:52 PM
$HROW Nice cute marketing trick. Now lets see the RXs. New reps should drive NRXs, keeping those at high level. And when refill rate high, TRXs is going to much higher.
0 · Reply
Finnish_boy
Finnish_boy May. 29 at 8:49 PM
$HROW
0 · Reply
Finnish_boy
Finnish_boy May. 29 at 8:49 PM
$HROW HELLO
0 · Reply
Finnish_boy
Finnish_boy May. 29 at 8:48 PM
$HROW Yes show up.. show me the goggles
0 · Reply
Finnish_boy
Finnish_boy May. 29 at 8:46 PM
$HROW This is better marketing than expensive Julie Bowen or hangover chinese guy. Data based marketing. VEVYE is cooking H2 2026. Exciting
0 · Reply
Finnish_boy
Finnish_boy May. 29 at 8:39 PM
$HROW There were literally a hundred posts about this on LinkedIn. Nice marketing whatever this is.
0 · Reply
Finnish_boy
Finnish_boy May. 29 at 8:11 PM
$HROW Happy Vevye 3y birthday to everyone! Didn't remember until saw this video. Not selling any shares but i want to see $100 before i see another this kind of video. https://www.linkedin.com/posts/harrow-health-inc_vevye-happybirthday-patientfirst-activity-7466216358045847553-gIuj?utm_source=social_share_send&utm_medium=android_app&rcm=ACoAADMPKxABq6eEK6a8CxJ0qJ12vcb7ZmuYvRc&utm_campaign=copy_link
0 · Reply
Finnish_boy
Finnish_boy May. 29 at 4:27 PM
$HROW Yes very bright future
1 · Reply
Finnish_boy
Finnish_boy May. 29 at 3:30 PM
$HROW If true, huge.
0 · Reply
Finnish_boy
Finnish_boy May. 29 at 3:30 PM
$HROW Verkazia press release next week or later.. lets see
0 · Reply
Latest News on HROW
Harrow to Present at William Blair's 46th Annual Growth Stock Conference

May 27, 2026, 7:00 AM EDT - 2 days ago

Harrow to Present at William Blair's 46th Annual Growth Stock Conference

Harrow CEO buys $302K, CFO buys $104.7K in common stock

2026-05-15T14:31:15.000Z - 14 days ago

Harrow CEO buys $302K, CFO buys $104.7K in common stock

Harrow price target lowered to $60 from $65 at B. Riley

2026-05-14T13:54:22.000Z - 15 days ago

Harrow price target lowered to $60 from $65 at B. Riley

Harrow price target lowered to $88 from $91 at Cantor Fitzgerald

2026-05-13T15:22:03.000Z - 16 days ago

Harrow price target lowered to $88 from $91 at Cantor Fitzgerald

Harrow Q1 Earnings Call Highlights

May 12, 2026, 11:11 AM EDT - 17 days ago

Harrow Q1 Earnings Call Highlights

Harrow Earnings Call Transcript: Q1 2026

May 12, 2026, 8:00 AM EDT - 17 days ago

Harrow Earnings Call Transcript: Q1 2026

Harrow Earnings release: Q1 2026

May 12, 2026, 8:00 AM EDT - 17 days ago

Harrow Earnings release: Q1 2026

Harrow Quarterly report: Q1 2026

May 12, 2026, 8:00 AM EDT - 17 days ago

Harrow Quarterly report: Q1 2026

Harrow Shareholder letter: Q1 2026

May 12, 2026, 8:00 AM EDT - 17 days ago

Harrow Shareholder letter: Q1 2026

Harrow Slides: Q1 2026

May 12, 2026, 8:00 AM EDT - 17 days ago

Harrow Slides: Q1 2026

Harrow reports Q1 EPS (74c) vs. (50c) last year

2026-05-11T20:41:15.000Z - 18 days ago

Harrow reports Q1 EPS (74c) vs. (50c) last year

Harrow Announces First Quarter 2026 Financial Results

May 11, 2026, 4:05 PM EDT - 18 days ago

Harrow Announces First Quarter 2026 Financial Results

Harrow To Report First Quarter 2026 Financial Results After Market Close on May 11, 2026

Apr 27, 2026, 7:00 AM EDT - 4 weeks ago

Harrow To Report First Quarter 2026 Financial Results After Market Close on May 11, 2026

Harrow Proxy statement: Proxy filing

Apr 24, 2026, 8:00 AM EDT - 5 weeks ago

Harrow Proxy statement: Proxy filing

Harrow Proxy statement: Proxy filing

Apr 24, 2026, 8:00 AM EDT - 5 weeks ago

Harrow Proxy statement: Proxy filing

Harrow announces issuance of J-Code for Iopidine 1%

2026-04-16T11:57:26.000Z - 6 weeks ago

Harrow announces issuance of J-Code for Iopidine 1%

Harrow Announces the Issuance of J-Code for IOPIDINE® 1%

Apr 16, 2026, 7:00 AM EDT - 6 weeks ago

Harrow Announces the Issuance of J-Code for IOPIDINE® 1%

Harrow selects LogiCare3PL as distribution partner

2026-04-14T14:35:13.000Z - 6 weeks ago

Harrow selects LogiCare3PL as distribution partner

LogiCare3PL Selected as Distribution Partner by Harrow

Apr 14, 2026, 10:30 AM EDT - 6 weeks ago

LogiCare3PL Selected as Distribution Partner by Harrow

Harrow management to meet virtually with BTIG

2026-04-09T20:33:07.000Z - 7 weeks ago

Harrow management to meet virtually with BTIG

Harrow management to meet virtually with BTIG

2026-04-09T20:25:15.000Z - 7 weeks ago

Harrow management to meet virtually with BTIG

Harrow price target lowered to $65 from $74 at B. Riley

2026-04-07T13:01:36.000Z - 7 weeks ago

Harrow price target lowered to $65 from $74 at B. Riley

Harrow price target lowered to $65 from $74 at B. Riley

2026-04-07T12:28:56.000Z - 7 weeks ago

Harrow price target lowered to $65 from $74 at B. Riley

Harrow Announces Pricing of $50.0 Million Offering of Senior Unsecured Notes Due 2030

Mar 24, 2026, 4:57 PM EDT - 2 months ago

Harrow Announces Pricing of $50.0 Million Offering of Senior Unsecured Notes Due 2030

Harrow Announces Add-On Offering of $50.0 Million of Senior Unsecured Notes to Support Growth

Mar 24, 2026, 8:15 AM EDT - 2 months ago

Harrow Announces Add-On Offering of $50.0 Million of Senior Unsecured Notes to Support Growth

Harrow Announces Three Abstracts Accepted for Presentation at ASCRS 2026 Annual Meeting

Mar 18, 2026, 7:00 AM EDT - 2 months ago

Harrow Announces Three Abstracts Accepted for Presentation at ASCRS 2026 Annual Meeting

Harrow Transcript: Leerink Global Healthcare Conference 2026

Mar 10, 2026, 8:40 AM EDT - 2 months ago

Harrow Transcript: Leerink Global Healthcare Conference 2026

Harrow Slides: FY 2026

Mar 10, 2026, 8:40 AM EDT - 2 months ago

Harrow Slides: FY 2026

Harrow price target lowered to $60 from $70 at Lake Street

2026-03-04T13:45:34.000Z - 3 months ago

Harrow price target lowered to $60 from $70 at Lake Street

Harrow price target lowered to $91 from $94 at Cantor Fitzgerald

2026-03-04T13:35:02.000Z - 3 months ago

Harrow price target lowered to $91 from $94 at Cantor Fitzgerald

Harrow price target lowered to $62 from $66 at Ladenburg

2026-03-04T12:41:07.000Z - 3 months ago

Harrow price target lowered to $62 from $66 at Ladenburg

Harrow to Present at Leerink Partner's 2026 Global Healthcare Conference

Mar 4, 2026, 7:00 AM EST - 3 months ago

Harrow to Present at Leerink Partner's 2026 Global Healthcare Conference

Harrow price target raised to $70 from $69 at H.C. Wainwright

2026-03-04T11:12:28.000Z - 3 months ago

Harrow price target raised to $70 from $69 at H.C. Wainwright

Harrow Earnings Call Transcript: Q4 2025

Mar 3, 2026, 8:00 AM EST - 3 months ago

Harrow Earnings Call Transcript: Q4 2025

Harrow Shareholder letter: Q4 2025

Mar 3, 2026, 8:00 AM EST - 3 months ago

Harrow Shareholder letter: Q4 2025

Harrow Annual report: Q4 2025

Mar 3, 2026, 8:00 AM EST - 3 months ago

Harrow Annual report: Q4 2025

Harrow Earnings release: Q4 2025

Mar 3, 2026, 8:00 AM EST - 3 months ago

Harrow Earnings release: Q4 2025

Harrow Slides: Q4 2025

Mar 3, 2026, 8:00 AM EST - 3 months ago

Harrow Slides: Q4 2025

Harrow announces U.S. FDA cleared an IND application for trial of Triesence

2026-03-03T12:16:07.000Z - 3 months ago

Harrow announces U.S. FDA cleared an IND application for trial of Triesence

Harrow to Initiate Phase 3 Clinical Trial Seeking to Expand TRIESENCE® Label to Include Ocular Inflammation and Pain Following Cataract Surgery Indication

Mar 3, 2026, 7:00 AM EST - 3 months ago

Harrow to Initiate Phase 3 Clinical Trial Seeking to Expand TRIESENCE® Label to Include Ocular Inflammation and Pain Following Cataract Surgery Indication

Harrow sees FY26 revenue $350M-$365M, consensus $386.39M

2026-03-02T21:39:03.000Z - 3 months ago

Harrow sees FY26 revenue $350M-$365M, consensus $386.39M

Harrow reports Q4 EPS 17c vs. 24c last year

2026-03-02T21:26:50.000Z - 3 months ago

Harrow reports Q4 EPS 17c vs. 24c last year

Harrow Announces Q4 and Full-Year 2025 Financial Results and 2026 Financial Guidance

Mar 2, 2026, 4:05 PM EST - 3 months ago

Harrow Announces Q4 and Full-Year 2025 Financial Results and 2026 Financial Guidance

Harrow To Report Fourth Quarter and Year-End 2025 Financial Results After Market Close on March 2, 2026

Feb 18, 2026, 7:00 AM EST - 3 months ago

Harrow To Report Fourth Quarter and Year-End 2025 Financial Results After Market Close on March 2, 2026

Harrow Announces Cash-Pay Direct-to-Prescriber PharmaPack™ Kits

Feb 17, 2026, 7:00 AM EST - 3 months ago

Harrow Announces Cash-Pay Direct-to-Prescriber PharmaPack™ Kits

Harrow Reaffirms 2025 Full-Year Revenue Guidance of $270–$280 Million, Marking Another Year of Strong Growth

Feb 2, 2026, 7:00 AM EST - 4 months ago

Harrow Reaffirms 2025 Full-Year Revenue Guidance of $270–$280 Million, Marking Another Year of Strong Growth

Harrow Transcript: Piper Sandler 37th Annual Healthcare Conference

Dec 2, 2025, 3:00 PM EST - 6 months ago

Harrow Transcript: Piper Sandler 37th Annual Healthcare Conference

Harrow to Present at Two Investor Conferences in December

Nov 24, 2025, 7:00 AM EST - 6 months ago

Harrow to Present at Two Investor Conferences in December

Harrow Announces Closing of Acquisition of Melt Pharmaceuticals

Nov 18, 2025, 7:00 AM EST - 6 months ago

Harrow Announces Closing of Acquisition of Melt Pharmaceuticals

Harrow Earnings Call Transcript: Q3 2025

Nov 11, 2025, 8:00 AM EST - 7 months ago

Harrow Earnings Call Transcript: Q3 2025

Harrow Quarterly report: Q3 2025

Nov 11, 2025, 8:00 AM EST - 7 months ago

Harrow Quarterly report: Q3 2025

Harrow Earnings release: Q3 2025

Nov 11, 2025, 8:00 AM EST - 7 months ago

Harrow Earnings release: Q3 2025

Harrow Slides: Q3 2025

Nov 11, 2025, 8:00 AM EST - 7 months ago

Harrow Slides: Q3 2025

Harrow Announces Third Quarter 2025 Financial Results

Nov 10, 2025, 4:05 PM EST - 7 months ago

Harrow Announces Third Quarter 2025 Financial Results

Harrow To Report Third Quarter 2025 Financial Results After Market Close on November 10, 2025

Oct 27, 2025, 7:00 AM EDT - 7 months ago

Harrow To Report Third Quarter 2025 Financial Results After Market Close on November 10, 2025

ImprimisRx Announces Leadership Changes

Oct 6, 2025, 7:00 AM EDT - 8 months ago

ImprimisRx Announces Leadership Changes

Harrow Transcript: Investor Day 2025

Sep 26, 2025, 11:30 AM EDT - 8 months ago

Harrow Transcript: Investor Day 2025

Harrow Slides: FY 2025

Sep 26, 2025, 11:30 AM EDT - 8 months ago

Harrow Slides: FY 2025

Harrow to Acquire Melt Pharmaceuticals

Sep 26, 2025, 7:00 AM EDT - 8 months ago

Harrow to Acquire Melt Pharmaceuticals

Harrow Launches Harrow Access for All (HAFA)

Sep 25, 2025, 4:05 PM EDT - 8 months ago

Harrow Launches Harrow Access for All (HAFA)

Harrow Announces Agenda and Speakers for Investor & Analyst Day

Sep 15, 2025, 7:00 AM EDT - 9 months ago

Harrow Announces Agenda and Speakers for Investor & Analyst Day

Harrow Announces Pricing of $250.0 Million Offering of Senior Unsecured Notes Due 2030

Sep 8, 2025, 5:57 PM EDT - 9 months ago

Harrow Announces Pricing of $250.0 Million Offering of Senior Unsecured Notes Due 2030

Harrow Announces Offering of $250.0 Million Senior Unsecured Notes Due 2030

Sep 8, 2025, 8:00 AM EDT - 9 months ago

Harrow Announces Offering of $250.0 Million Senior Unsecured Notes Due 2030

Harrow Transcript: H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

Aug 13, 2025, 8:30 AM EDT - 10 months ago

Harrow Transcript: H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

Harrow Earnings Call Transcript: Q2 2025

Aug 12, 2025, 8:00 AM EDT - 10 months ago

Harrow Earnings Call Transcript: Q2 2025

Harrow Quarterly report: Q2 2025

Aug 12, 2025, 8:00 AM EDT - 10 months ago

Harrow Quarterly report: Q2 2025

Harrow Earnings release: Q2 2025

Aug 12, 2025, 8:00 AM EDT - 10 months ago

Harrow Earnings release: Q2 2025

Harrow Slides: Q2 2025

Aug 12, 2025, 8:00 AM EDT - 10 months ago

Harrow Slides: Q2 2025

Harrow Announces Second-Quarter 2025 Financial Results

Aug 11, 2025, 4:01 PM EDT - 10 months ago

Harrow Announces Second-Quarter 2025 Financial Results

Harrow Slides: Corporate Presentation

Aug 11, 2025, 7:00 AM EDT - 10 months ago

Harrow Slides: Corporate Presentation

Harrow to Present at H.C. Wainwright 5th Annual Ophthalmology Conference

Aug 6, 2025, 7:00 AM EDT - 10 months ago

Harrow to Present at H.C. Wainwright 5th Annual Ophthalmology Conference

Harrow To Report Second Quarter 2025 Financial Results After Market Close on August 11, 2025

Jul 29, 2025, 7:00 AM EDT - 10 months ago

Harrow To Report Second Quarter 2025 Financial Results After Market Close on August 11, 2025

Harrow Enters into Commercialization Agreement with Samsung Bioepis for Ophthalmology Biosimilars Portfolio in the United States

Jul 17, 2025, 7:00 AM EDT - 11 months ago

Harrow Enters into Commercialization Agreement with Samsung Bioepis for Ophthalmology Biosimilars Portfolio in the United States

Samsung Bioepis Enters into a Partnership with Harrow for Commercialization of Ophthalmology Biosimilars Portfolio in the United States

Jul 17, 2025, 7:00 AM EDT - 11 months ago

Samsung Bioepis Enters into a Partnership with Harrow for Commercialization of Ophthalmology Biosimilars Portfolio in the United States

Harrow Appoints Mike Biega as Vice President of Investor Relations and Communications

Jun 18, 2025, 7:00 AM EDT - 1 year ago

Harrow Appoints Mike Biega as Vice President of Investor Relations and Communications

Harrow Acquires U.S. Commercial Rights to BYQLOVI™ (Clobetasol Propionate Ophthalmic Suspension) 0.05% from Formosa Pharmaceuticals

Jun 9, 2025, 7:00 AM EDT - 1 year ago

Harrow Acquires U.S. Commercial Rights to BYQLOVI™ (Clobetasol Propionate Ophthalmic Suspension) 0.05% from Formosa Pharmaceuticals

Harrow to Present at Two Investor Conferences in May

May 14, 2025, 7:00 AM EDT - 1 year ago

Harrow to Present at Two Investor Conferences in May

Harrow Earnings Call Transcript: Q1 2025

May 9, 2025, 8:00 AM EDT - 1 year ago

Harrow Earnings Call Transcript: Q1 2025

Harrow Quarterly report: Q1 2025

May 9, 2025, 8:00 AM EDT - 1 year ago

Harrow Quarterly report: Q1 2025

Harrow Earnings release: Q1 2025

May 9, 2025, 8:00 AM EDT - 1 year ago

Harrow Earnings release: Q1 2025

Harrow Slides: Q1 2025

May 9, 2025, 8:00 AM EDT - 1 year ago

Harrow Slides: Q1 2025

Harrow Announces First-Quarter 2025 Financial Results

May 8, 2025, 4:01 PM EDT - 1 year ago

Harrow Announces First-Quarter 2025 Financial Results

Harrow to Report First Quarter 2025 Financial Results After Market Close on May 8, 2025

May 5, 2025, 7:00 AM EDT - 1 year ago

Harrow to Report First Quarter 2025 Financial Results After Market Close on May 8, 2025

Harrow Proxy statement: Proxy Filing

Apr 25, 2025, 8:00 AM EDT - 1 year ago

Harrow Proxy statement: Proxy Filing

Harrow Proxy statement: Proxy Filing

Apr 25, 2025, 8:00 AM EDT - 1 year ago

Harrow Proxy statement: Proxy Filing

NORDIC GROUP B.V. THROUGH ITS SUBSIDIARY NORDIC PHARMA, INC.

Apr 24, 2025, 10:00 AM EDT - 1 year ago

NORDIC GROUP B.V. THROUGH ITS SUBSIDIARY NORDIC PHARMA, INC.

Harrow Expands VEVYE® Access for All Program to ImprimisRx's Klarity-C Patients

Apr 10, 2025, 7:00 AM EDT - 1 year ago

Harrow Expands VEVYE® Access for All Program to ImprimisRx's Klarity-C Patients

Harrow Earnings Call Transcript: Q4 2024

Mar 28, 2025, 8:00 AM EDT - 1 year ago

Harrow Earnings Call Transcript: Q4 2024

Harrow Earnings release: Q4 2024

Mar 28, 2025, 8:00 AM EDT - 1 year ago

Harrow Earnings release: Q4 2024

Harrow Annual report: Q4 2024

Mar 28, 2025, 8:00 AM EDT - 1 year ago

Harrow Annual report: Q4 2024

Harrow Slides: Q4 2024

Mar 28, 2025, 8:00 AM EDT - 1 year ago

Harrow Slides: Q4 2024

Harrow Announces Fourth-Quarter and Year-End 2024 Audited Financial Results

Mar 27, 2025, 4:01 PM EDT - 1 year ago

Harrow Announces Fourth-Quarter and Year-End 2024 Audited Financial Results

Harrow To Report Fourth Quarter and Audited Year-End 2024 Financial Results After Market Close on March 27, 2025

Mar 27, 2025, 10:45 AM EDT - 1 year ago

Harrow To Report Fourth Quarter and Audited Year-End 2024 Financial Results After Market Close on March 27, 2025

Harrow Announces Transitional Pass-Through Reimbursement Status for TRIESENCE® (Triamcinolone Acetonide Injectable Suspension) 40 mg/mL

Mar 24, 2025, 7:00 AM EDT - 1 year ago

Harrow Announces Transitional Pass-Through Reimbursement Status for TRIESENCE® (Triamcinolone Acetonide Injectable Suspension) 40 mg/mL

Harrow Provides Fourth Quarter and Year-End 2024 Unaudited Preliminary Financial Results and 2025 Revenue Guidance

Mar 17, 2025, 4:01 PM EDT - 1 year ago

Harrow Provides Fourth Quarter and Year-End 2024 Unaudited Preliminary Financial Results and 2025 Revenue Guidance

Harrow Launches VEVYE® Access for All

Mar 17, 2025, 7:00 AM EDT - 1 year ago

Harrow Launches VEVYE® Access for All

Harrow Executes Five-Year Strategic Supply and Development Agreement for TRIESENCE®

Mar 11, 2025, 7:00 AM EDT - 1 year ago

Harrow Executes Five-Year Strategic Supply and Development Agreement for TRIESENCE®

Harrow to Report Fourth Quarter and Year-End 2024 Financial Results After Market Close on March 17, 2025

Mar 3, 2025, 7:15 AM EST - 1 year ago

Harrow to Report Fourth Quarter and Year-End 2024 Financial Results After Market Close on March 17, 2025

Harrow Partners with Cencora to Launch “Harrow Cares” Program, Making IHEEZO® and TRIESENCE® More Accessible and Affordable for Retina Specialists and Their Patients

Jan 27, 2025, 7:30 AM EST - 1 year ago

Harrow Partners with Cencora to Launch “Harrow Cares” Program, Making IHEEZO® and TRIESENCE® More Accessible and Affordable for Retina Specialists and Their Patients

COR

Finnish_boy
Finnish_boy May. 29 at 8:52 PM
$HROW Nice cute marketing trick. Now lets see the RXs. New reps should drive NRXs, keeping those at high level. And when refill rate high, TRXs is going to much higher.
0 · Reply
Finnish_boy
Finnish_boy May. 29 at 8:49 PM
$HROW
0 · Reply
Finnish_boy
Finnish_boy May. 29 at 8:49 PM
$HROW HELLO
0 · Reply
Finnish_boy
Finnish_boy May. 29 at 8:48 PM
$HROW Yes show up.. show me the goggles
0 · Reply
Finnish_boy
Finnish_boy May. 29 at 8:46 PM
$HROW This is better marketing than expensive Julie Bowen or hangover chinese guy. Data based marketing. VEVYE is cooking H2 2026. Exciting
0 · Reply
Finnish_boy
Finnish_boy May. 29 at 8:39 PM
$HROW There were literally a hundred posts about this on LinkedIn. Nice marketing whatever this is.
0 · Reply
Finnish_boy
Finnish_boy May. 29 at 8:11 PM
$HROW Happy Vevye 3y birthday to everyone! Didn't remember until saw this video. Not selling any shares but i want to see $100 before i see another this kind of video. https://www.linkedin.com/posts/harrow-health-inc_vevye-happybirthday-patientfirst-activity-7466216358045847553-gIuj?utm_source=social_share_send&utm_medium=android_app&rcm=ACoAADMPKxABq6eEK6a8CxJ0qJ12vcb7ZmuYvRc&utm_campaign=copy_link
0 · Reply
Finnish_boy
Finnish_boy May. 29 at 4:27 PM
$HROW Yes very bright future
1 · Reply
Finnish_boy
Finnish_boy May. 29 at 3:30 PM
$HROW If true, huge.
0 · Reply
Finnish_boy
Finnish_boy May. 29 at 3:30 PM
$HROW Verkazia press release next week or later.. lets see
0 · Reply
flash9875
flash9875 May. 29 at 3:22 PM
$HROW hearing that dell mu and nvda use vevye as a lubricant in their chips….
0 · Reply
Finnish_boy
Finnish_boy May. 29 at 3:21 PM
$HROW Whole dip can be gone in 2 weeks. Stupid casino i say.
0 · Reply
Finnish_boy
Finnish_boy May. 29 at 12:28 PM
$HROW Ensuring that Boll hasn't accidentally used Lucentis list price for Byooviz
2 · Reply
Finnish_boy
Finnish_boy May. 29 at 12:20 PM
$HROW Is stock bottomed? Yes. Byooviz launch in a month💪🏼
1 · Reply
Finnish_boy
Finnish_boy May. 29 at 12:18 PM
$HROW Biggest catalyst: Kicked out Makary buys back all the shares that he was forced to sell😂
0 · Reply
Finnish_boy
Finnish_boy May. 29 at 9:40 AM
$HROW Lets hear the call on Wednesday, is there any new nuggets.
0 · Reply
Finnish_boy
Finnish_boy May. 29 at 9:38 AM
$HROW Every bear will be absolutely crushed. YEAH! We can see pullback (geopolitical issues, inflation, yields whatever) but those are always buying opportunitites. HROW is my best pick for year ahead. I missed many stocks but i will nail this game eventually!
0 · Reply
Finnish_boy
Finnish_boy May. 29 at 9:34 AM
$HROW Yeah, HROW to ATH this year. Next year $100. S&P500 to 8,000. AI boom is insane. Be ready. E.g NVIDIA stock is very cheap. People will be surprised. "Investors still don’t understand how massive the demand for AI is going to be. Case: Dell. The stock has risen 153% since the beginning of the year. After yesterday’s earnings release (published after market close), the stock reacted by surging 40%, as AI-related demand surprised investors."
1 · Reply
flash9875
flash9875 May. 29 at 2:29 AM
$HROW good job fin…keep buying !
0 · Reply
Stacks_Edwards
Stacks_Edwards May. 28 at 5:40 PM
$HROW green on all shares. Let’s goo!!
0 · Reply
Fullback
Fullback May. 28 at 11:35 AM
$HROW Shorts continue to hang around:
0 · Reply
Finnish_boy
Finnish_boy May. 27 at 4:30 PM
$HROW Next year growth can be more like 40% not sure. Bc i have no idea how big opuviz will be. Iheezo and vevye growth will be solid for sure. If opuviz big, then >40% possible for sure.
4 · Reply